Company announce 28-Day Clinical Outcomes Data from Mavrilimumab Open-Label Treatment Protocol in Severe COVID-19 Pneumonia and active U.S. investigational new drug application for Phase 2/3 Clinical Trial

Patients treated with mavrilimumab, anantibody that targets GM-CSFRα, experienced earlier and improved clinical outcomes than control-group patients, including earlier weaning from supplemental oxygen, shorter hospitalizations, and no deaths.


Biospace Inc.